Medtronic is a medical devices business based in the US. Medtronic shares (MDT) are listed on the NYSE and all prices are listed in US Dollars. Medtronic employs 95,000 staff and has a trailing 12-month revenue of around $32.6 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $89.89 |
|---|---|
| 52-week range | $67.11 - $90.13 |
| 50-day moving average | $81.41 |
| 200-day moving average | $82.53 |
| Wall St. target price | $93.87 |
| PE ratio | 29.8249 |
| Dividend yield | $2.77 (3.16%) |
| Earnings per share (TTM) | $2.97 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $89.89 from 2024-09-06
| 1 week (2024-08-30) | 1.48% |
|---|---|
| 1 month (2024-08-07) | 10.85% |
| 3 months (2024-06-07) | 6.92% |
| 6 months (2024-03-07) | 5.57% |
| 1 year (2023-09-07) | 12.46% |
|---|---|
| 2 years (2022-09-07) | 10.36% |
| 3 years (2021-09-07) | 122.7409 |
| 5 years (2019-09-06) | 104.0896 |
Valuing Medtronic stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Medtronic's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Medtronic's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 30x. In other words, Medtronic shares trade at around 30x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Medtronic's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.6407. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Medtronic's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Medtronic's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $9.1 billion.
The EBITDA is a measure of a Medtronic's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $32.6 billion |
|---|---|
| Operating margin TTM | 17.61% |
| Gross profit TTM | $21.7 billion |
| Return on assets TTM | 4.48% |
| Return on equity TTM | 7.95% |
| Profit margin | 12.06% |
| Book value | $37.39 |
| Market Capitalization | $113.6 billion |
TTM: trailing 12 months
Dividend payout ratio: 53.05% of net profits
Recently Medtronic has paid out, on average, around 53.05% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.16% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Medtronic shareholders could enjoy a 3.16% return on their shares, in the form of dividend payments. In Medtronic's case, that would currently equate to about $2.77 per share.
Medtronic's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Medtronic's most recent dividend payout was on 10 October 2024. The latest dividend was paid out to all shareholders who bought their shares by 26 September 2024 (the "ex-dividend date").
Medtronic's shares were split on a 2:1 basis on 26 September 1999. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Medtronic shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Medtronic shares which in turn could have impacted Medtronic's share price.
Over the last 12 months, Medtronic's shares have ranged in value from as little as $67.1102 up to $90.13. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Medtronic's is 0.831. This would suggest that Medtronic's shares are less volatile than average (for this exchange).
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system.
Use this calculator to quickly see potential outcomes of your options trades.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.